| Ytd | 59.04% | |
| 1y | 825.16% |
| Open | 28.49 | Prev Close | 28.29 | Low | 28.00 | High | 28.49 | Mkt Cap | 992.11M |
| Vol | 4.88K | Avg Vol | 503.61K | EPS | -2.42 | P/E | -11.68 | Forward P/E | -8.35 |
| Beta | 1.06 | Short Ratio | 4.20 | Inst. Own | 84.80% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-12 | 50-d Avg | 24.89 | 200-d Avg | 20.17 | 1yr Est | 35.64 |
ANRO News
Shares of Alto Neuroscience, Inc. (NYSE: ANRO - Get Free Report) have earned a consensus recommendat
Alto Neuroscience maintains a 'Buy' rating, driven by the potential of ALTO-207 for treatment-resist
Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO), a clinical-stage biopharmaceutical company wit
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO)
On July 13, 2026, Alto Neuroscience, Inc. (the "Company") announced that, based upon prelimi
Independent, peer-reviewed, placebo-controlled trial conducted by Lund University showed pramipexole
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO)
Alto Neuroscience, Inc. (âAltoâ) (NYSE: ANRO), a clinical-stage biopharmaceutical company focuse
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO)
Baird analyst Brian Skorney maintains Alto Neuroscience (NYSE:ANRO) with a Outperform and lowers
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (NYSE: ANRO), a clini
Wedbush analyst Laura Chico maintains Alto Neuroscience (NYSE:ANRO) with a Neutral and raises the
Alto Neuroscience (NYSE:ANRO) reported quarterly losses of $(0.80) per share which missed the analys
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO)
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO)
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Alto Neuroscience (NYSE:ANRO) with
Alto Neuroscience, Inc. (NYSE:ANRO), a clinical-stage biopharmaceutical company focused on precision
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (NYSE: ANRO), a clini
— Phase 2b closely resembles PAX-D study design, which demonstrated an effect size for pramipexole m
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (NYSE: ANRO), a clini
6,000,000 SharesCommon Stock Offered by the Selling StockholdersThis prospectus relates to the propo
Alto Neuroscience, Inc. (NYSE: ANRO - Get Free Report)'s share price gapped down before the market o
Baird analyst Brian Skorney maintains Alto Neuroscience (NYSE:ANRO) with a Outperform and lowers
US stocks fall, Dow drops over 50 points, real estate shares rise, Acuity Inc. shares decline, Sky Q
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Alto Neuroscience (NYSE:ANRO) with
Jones Trading analyst Justin Walsh maintains Alto Neuroscience (NYSE:ANRO) with a Buy and lowers
Wedbush analyst Laura Chico maintains Alto Neuroscience (NYSE:ANRO) with a Neutral and lowers the
Dow futures down 400 points, Alto Neuroscience shares dip 13.6% after Phase 2 trial results, other s
Amazon may acquire Globalstar Inc., shares soared in pre-market trading. Other gainers include Turbo
— In the proof-of-concept study, ALTO-101 did not achieve statistical significance on primary endpoi
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage bioph
Baird analyst Brian Skorney maintains Alto Neuroscience (NYSE:ANRO) with a Outperform and raises
Wedbush analyst Laura Chico maintains Alto Neuroscience (NYSE:ANRO) with a Neutral and raises the
– Financing led by Commodore Capital with participation from new and existing biotech focused invest
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO)
Alto Neuroscience (NYSE:ANRO) reported quarterly losses of $(0.45) per share which beat the analyst
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO)
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO)
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO)
BTIG analyst Thomas Shrader maintains Alto Neuroscience (NYSE:ANRO) with a Buy and raises the pri
Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO), a clinical-stage biopharmaceutical company foc
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO)
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #Neuroplasticity--Alto Neuroscience, Inc. (“Alto”)
– Issued and pending claims expected to protect ALTO-207 into the mid-2040s –Alto Neuroscience, Inc.
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO)
